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What you need to know
• Palliative radiotherapy offers effective symptom control for focal disease
due to cancer
• Increased analgesia, anti-emetics, and in some cases corticosteroids
can help to reduce discomfort and side effects
• Acute side effects of radiotherapy usually resolve within 4-6 weeks of
completing treatment
• Symptoms of cancer may deteriorate before improvement
• For patients in the final weeks of life, the side effects and disruption of
palliative radiotherapy may outweigh the benefits, and holistic palliative
care may be more appropriate
Palliative radiotherapy offers a quick, inexpensive, and effective
way of reducing many of the focal symptoms of advanced,
incurable cancer, whether these arise from the primary tumour
or from metastatic deposits. It can improve quality of life while
being associated with limited treatment burden in terms of both
hospital attendances and side effects.1 The average UK general
practice oversees care for around 20 patients with terminal
cancer each year with higher numbers seen in secondary care,2 3
while a Canadian survey of general practitioners found that 85%
had provided care for patients with advanced cancer within the
previous month.4 This article aims to update non-specialists on
the benefits, practicalities, and side effects of palliative
radiotherapy to ensure that patients are considered and referred
for these treatments when appropriate.
Sources and selection criteria
In developing this article, we used multiple sources. For each of the sites
treated, we carried out a search of the Cochrane database to identify
systematic reviews. Search terms used included “palliative AND radiotherapy
AND bone metastases,” “spinal cord compression AND radiotherapy,” and
“palliative radiotherapy AND lung cancer.” Where no Cochrane reviews were
identified, we used Medline searches to identify other relevant systematic
reviews and individual studies. We also searched our existing collections of
relevant references and consulted appropriate experts where relevant studies
could not be identified. In all cases we used the highest level of evidence
available to inform this review, with more recent studies cited where possible.
All searches were carried out between September 2017 and January 2018.
How is radiotherapy delivered?
Radiotherapy is delivered with linear accelerators (fig 1) in
specialised cancer centres generally located in large urban areas
(see box 1). High energy x rays are targeted to the disease site,
causing DNA damage and cell death. Curative radiotherapy is
routinely delivered over multiple, small daily doses (fractions)
to reduce the risk of long term, permanent side effects in
adjacent normal tissues.5 Palliative treatments require lower
total doses, with the focus shifting to symptom control while
minimising treatment burden. This change underpins the routine
delivery of palliative radiotherapy using much shorter courses
of larger fraction size (hypo-fractionation).
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Box 1: Practicalities of palliative radiotherapy
• Anatomically targeted treatment during which the patient lies still on a
relatively hard-topped treatment couch for about 15 minutes. The
procedure itself is not associated with pain, but some may find the
treatment position uncomfortable. Increased pain relief ahead of
treatment can help. Occasionally this discomfort outweighs the benefits
• Patients must be able to provide informed consent. In emergency
situations (such as spinal cord compression) a decision may be made
in the patient’s best interests if the patient lacks capacity and has no
available representative
• Patients must be able to follow verbal commands from radiographers
outside the treatment room; a lack of capacity may make it difficult or
even unsafe to deliver treatment. Sedation and anaesthesia are not
routinely used for palliative radiotherapy
• Palliative treatments are usually delivered as a single dose or a short
course (usually over 1-3 weeks)
• A close fitting mask maybe needed to ensure a consistent treatment
position for treatments to the head, neck or upper chest (fig 2). This is
generally well tolerated, even by more anxious patients
• Re-treatment may be possible for recurrent symptoms, but side effects
may be greater
• Referrals and management of treatment related side effects can be
discussed with the local radiotherapy department
Increasingly, advanced techniques are used to offer more precise
treatment delivery, allowing increased dose to the tumour while
maintaining limited dose to surrounding tissues (stereotactic
radiotherapy) (see fig 3).
What are the main barriers to referral for
palliative radiotherapy?
Despite increasing numbers of radiotherapy treatment machines
in the UK,6 national data highlight that radiotherapy use is lower
than in Europe.7-10 Internationally, multiple population based
studies have shown that the chances of receiving palliative
radiotherapy are dictated not only by clinical need but also by
factors such as age, deprivation, and distance from treatment
centre.11 12 Questionnaire based studies suggest that a lack of
understanding of the benefits of palliative radiotherapy among
general practitioners and palliative care specialists may also be
a barrier to referral.13-15
What are the indications for using
palliative radiotherapy?
A wide range of focal symptoms from advanced cancer can be
treated with palliative radiotherapy as described below (and in
table 1). Patients can undergo radiotherapy alongside palliative
systemic anticancer treatments.
Given that radiotherapy can only ever address focal disease,
these treatments should supplement, not replace holistic
palliative care. Assessment and support for all physical,
psychological, and social needs, with strong communication
between services, are necessary. Palliative radiotherapy rarely
improves overall survival, which is reported to be a median of
5.2 months in one observational study.43 For patients with
particularly limited prognosis, careful consideration of the
appropriate level of intervention is essential; the potential
benefits of treatment may be outweighed by expected side
effects and treatment burden.
Pain due to bone metastases
Postmortem studies have detected bone metastases in up to 70%
of patients with advanced cancer.44 Such metastases often cause
localised pain and account for 35-40% of all palliative
radiotherapy treatments.45 Pain may be constant or intermittent,
can be neuropathic with a radiating dermatomal component and
possible altered sensation, and often limits activities of daily
living.46 Initial management combines analgesics and a holistic
assessment of needs with interventions as required, such as
home adaptations and walking aids.47 If, despite weak opioids,
patients have persistent pain or side effects of medication,
consider referral for radiotherapy.48 Metastases in long bones
have a risk of pathological fracture. When this risk is assessed
to be high, surgical stabilisation is often carried out before
radiotherapy.49-51
Palliative radiotherapy provides pain relief in a median of 2-3
weeks for 60% of patients (table 1).16 17 Where pain recurs,
retreatment can be considered after at least four weeks to allow
response.52 Intravenous bisphosphonates offered equivalent pain
relief to single fraction radiotherapy for metastatic prostate
cancer in a single randomised controlled trial.19 This may be an
alternative option for patients with prostate cancer naïve to
bisphosphonates.
Symptoms due to locally advanced thoracic
cancer
Lung cancer is the third commonest cancer in the UK and 28%
of patients will present with locally advanced disease.53 54
Thoracic symptoms include dyspnoea (50%), chest pain (28%),
cough (40%), haemoptysis (10%), and dysphagia (7%).22 Some
of these local symptoms can be successfully palliated in about
two thirds of patients, although the success rate varies with
symptoms. More information is provided in table 1.20 21
Palliative radiotherapy to the mediastinum improved obstructive
dysphagia from locally advanced oesophageal cancer in around
two thirds of patients after a median of four weeks in a
non-randomised phase I/II study.25 Given this delay in
improvement and the risk of deterioration due to acute
oesophagitis, patients with clinically significant dysphagia at
baseline often undergo oesophageal stenting before
radiotherapy.55 Radiotherapy improves durability of swallowing
function after stenting.26 27 However, for patients with very
limited prognosis, stenting alone can provide rapid relief of
dysphagia, and this group is unlikely to benefit from the addition
of palliative radiotherapy.
Symptomatic radiation pneumonitis (occurring in <5%) can
occur from six weeks to six months after treatment that includes
the lungs.20 21 Refer patients with cough and dyspnoea without
another clear cause to the treating oncologist urgently for
assessment and consideration of oral corticosteroids.
Pain and neurological compromise due to
malignant spinal cord compression
Malignant spinal cord compression occurs when vertebral
disease compresses the cord, either directly or as a result of
vertebral collapse. More rarely, intraspinal or epidural
metastases occur. Back pain is common, often occurring before
neurological signs and symptoms, including sensory and motor
disturbance and loss of sphincter control. Symptom progression
varies, from neurological deterioration over hours to a gradual
decline over weeks. Urgent magnetic resonance imaging (MRI)
is required to confirm the diagnosis, and oral dexamethasone
16 mg once daily (with proton pump inhibitor) is routinely
administered.56 57 Subsequent assessments target expected
prognosis in order to guide management decisions.58 59
The median overall survival after a diagnosis of malignant spinal
cord compression is 3-4 months.29 60 When predicted prognosis
is more than six months, neurosurgical decompression may be
considered before radiotherapy on the basis of a single
randomised study showing improved neurological outcomes.32
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Unfortunately, most patients have a prognosis of less than six
months. For these patients, urgent palliative radiotherapy (within
24 hours of MRI confirmation) aims to reduce pain and retain
or improve neurological function.56 The best neurological
outcomes are seen in those retaining some movement before
treatment or with gradual onset of neurological symptoms.61 For
patients with established paraplegia, less than 10% regain
mobility; in the absence of pain, and if the prognosis is very
limited, holistic palliative care and appropriate social or nursing
support may be more appropriate.62
Acute side effects reflect the vertebral level treated, while late
radiation induced spinal cord myelopathy is rarely seen with
palliative doses (<1%).63
Symptoms due to brain metastases
Brain metastases occur in 20-40% of individuals with systemic
cancer.34 Presentation can be with seizures, focal neurology, or
symptoms of raised intracranial pressure (nausea, vomiting, and
headaches). Prognostic indices help to tailor treatment to the
individual patient.64 65 For those with limited brain metastases
and a life expectancy of more than six months, neurosurgery or
stereotactic radiotherapy can be considered under discussion
with the treating team, local neurosurgical or neuro-oncology
teams, and patient.36 66
For those with more extensive cerebral disease who retain a
good performance status, whole brain radiotherapy can be
offered, although no high quality randomised data exists to
support this over corticosteroids alone.67 Indeed, a recent trial
demonstrated no survival or quality of life benefit from whole
brain radiotherapy over steroids alone in patients with brain
metastases from non-small cell lung cancer.33 This has resulted
in a reduction in the use of whole brain radiotherapy in this
situation, but extrapolation to other cancer diagnoses is unlikely
to be justified.
Symptoms due to advanced head and neck
cancer
Patients with locally advanced head and neck cancer often
present with a range of difficult to control symptoms including
pain, dysphagia or odynophagia, airway compromise, bleeding,
and cosmetically distressing tumour bulk.68 These often frail
patients have complex needs and require multidisciplinary
support including specialist nursing and medical care, support
from allied health professionals, palliative care, and community
support with strong communication between services.
Prospective studies report improvement in pain control and
quality of life in about 50-60% of patients after palliative
radiotherapy, with improved ability to eat solids in 33%.37 38 Of
note, in one UK series, 18% of patients required hospital
admission during or immediately after treatment for nutrition,
dehydration, and pain control.68
Symptoms due to advanced pelvic cancers
Locally advanced pelvic cancers can result in bleeding,
discharge, bowel obstruction, urinary disturbance, and pelvic
pain. Radiotherapy palliated bleeding in up to 90% of patients
with advanced bladder, rectal, or gynaecological cancer and
improved other symptoms for half to two thirds of
patients.39 40 42 69 Acute side effects frequently occur, alongside
temporary deterioration of existing symptoms. If abdominal
discomfort or diarrhoea are severe or fail to resolve with simple
measures, seek advice from the treating oncology team.
Bleeding, pain, and malodour due to skin
cancers
Symptoms of bleeding, pain, and malodour due to advanced
primary skin cancers responded to palliative radiotherapy in
61% of cases in a small observational study.70 Cutaneous
disease—most commonly arising from breast cancer (metastases
or primary), melanoma, and lung cancer71—can be treated
similarly, although the evidence is extremely limited and there
are no randomised comparisons with alternative approaches
(such as surgical resection, electro-chemotherapy, photodynamic
therapy, topical treatments).72 73
What are the most common side effects
of palliative radiotherapy?
The side effects of radiotherapy are dictated by which tissues
receive a substantial dose. For example, conventional
radiotherapy to lumbar spine vertebral metastases will usually
involve irradiation of the bowels, resulting in side effects related
to both the bone metastasis and bowels (see fig 3). Additionally,
treatment is associated with fatigue in at least two thirds of
patients, and this can affect quality of life, limiting participation
in preferred activities.74 75
Acute side effects of palliative radiotherapy usually resolve
within 4-6 weeks of completing treatment. In routine practice,
palliative prescribing of analgesia (including strong opiates)
and antiemetics underpins the management of side effects.
Randomised evidence is limited, and the recommendations for
management of side effects (see table 2) are predominantly
based on systematic reviews and guidelines.
Long term side effects are uncommon in palliative radiotherapy,
and management of these is led by the treating team with
multidisciplinary involvement when required.106
What new treatments can we expect?
The radiotherapy dose delivered to a tumour is usually limited
by likely side effects in surrounding tissues. Advanced
techniques that offer treatments more closely matched to the
tumour shape, delivered with computed tomography on the
treatment couch immediately before radiotherapy, can more
accurately target much higher radiotherapy doses to small focal
disease sites. These more targeted stereotactic treatments are
variously referred to as stereotactic body radiotherapy,
stereotactic ablative body radiotherapy, and stereotactic
radio-surgery. Figure 3 provides an example of the difference
in radiotherapy dose distribution between the simple
conventional palliative approach and these more complex
treatments.
There is now the potential for these higher dose stereotactic
treatments to be used to improve survival and quality of life in
patients with metastatic disease. This is being investigated for
“oligo-metastatic disease” (in which a patient has only a limited
number of metastatic deposits, and the disease has not become
widespread).115 For such patients, high dose stereotactic
treatments can be used to ablate all macroscopic sites of disease,
potentially resulting in superior overall survival. However, even
the existence of the oligo-metastatic state remains
controversial.110 A further possible role for these treatments is
in more advanced disease, where a higher radiotherapy dose to
a symptomatic metastasis might provide better and more durable
symptom control while continuing to deliver treatment in a
minimum number of fractions with limited toxicity to
surrounding tissues.108 109 111 There are no randomised data to
support either of these approaches currently. Their expected
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value remains controversial, and trials are now under way for
a range of indications.107-109 112 113 116
An additional area of palliative radiotherapy in which significant
advances are now being made is in the use of radionuclides.
These treatments deliver radioactive isotopes to tumour tissue,
either through anatomically targeted delivery (such as via the
hepatic artery in metastatic colorectal cancer) or through the
use of radiolabelled molecules or monoclonal antibodies which
are preferentially taken up by the tumour or its
microenvironment.117 Historically, their use has been limited to
some relatively rare tumours, but novel agents are increasingly
demonstrating benefits in a range of more common conditions
such as metastatic prostate cancer.114 With trials ongoing
internationally, these treatments are likely to be used more
extensively over the next few years.
A patient’s perspective
My late husband received palliative radiotherapy multiple times during his
treatment for multiple myeloma. Early in the course of his disease, radiotherapy
for back pain and spinal cord compression ensured that he was able to
continue the gardening he had always enjoyed. Receiving treatment was
never uncomfortable for him, but, as his general condition deteriorated towards
the end of his life, he spent more time in hospital and the benefits of
radiotherapy became less clear. He had a mask made for one of his treatments
which covered his head and neck: he didn’t find this particularly uncomfortable
and he was excited to show it to everyone. He even let his grandchildren play
with it once treatment was completed.
Education into practice
• Think about the last time you saw a patient with advanced cancer. How
much did you consider localised disease as a possible cause of their
symptoms?
• Would you feel confident referring them to discuss palliative radiotherapy
to help treat their symptoms?
• What else might you do differently as a result of reading this article?
How patients were involved in the creation of this article
A patient representative (a relative of a previously treated patient) had the
opportunity to review and comment on the draft manuscript. She did not feel
any changes to the manuscript were needed but did share her experiences
of her husband’s radiotherapy treatment.
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Tables
Table 1| Benefits of palliative radiotherapy for varying indications (evidence referenced is the highest level identified)
ResultsEndpointsStudy and sample sizeTreatments assessed
Pain due to bone metastases
60.7% response rate (OR for single v multiple fraction treatments
0.98 (95% CI 0.95 to 1.02)).
23.8% complete pain resolution.
Re-treatment higher after single fraction (OR 2.6 (1.92 to 3.47))
No significant difference in pathological fracture rate (overall 3.2%,
OR 1.10 (0.65 to 1.86))
Pain response, re-treatment rate,
pathological fracture rate.
Time point varied between trials
Chow et al 201216 (SR, 5617
patients, 25 trials)
Single fraction radiotherapy
v longer, more fractionated
courses.
59% response rate (OR for single v multiple fractions 1.03 (0.89 to
1.19)).
33% complete pain resolution.
Re-treatment rate higher after single fraction (21.5% v 7.4%, OR
3.44 (2.67 to 4.43)).
Fracture rate higher after single fraction (3% v 1.6%, OR 1.82 (1.06
to 3.11))
Pain response, re-treatment rate,
pathological fracture rate.
Time point varied between trials
Sze et al 200417 (SR, 3487
painful sites, 11 trials)
71% response rate; 35% complete resolution of pain; median time
to benefit 3 weeks.
Re-treatment rate higher after single fraction (25% v 7% (P<0.0001)).
Fracture rate higher after single fraction (4% v 2% (P<0.05))
Pain response in remaining
lifespan (1° endpoint),
re-treatment rate, pathological
fracture rate.
Assessed weekly
Steenland et al 199918 (RCT,
1157 patients)
53.1% response with radiotherapy v 49.5% with ibandronate
(difference 3.7% (−12.4% to 5.0%), P=0.49).
24% crossover with ibandronate v 31% with radiotherapy.
3% fracture rate with ibandronate v 2% with radiotherapy (P=0.31)
Pain response at 4 weeks (1°
endpoint), crossover, pathological
fracture rate.
Assessed 4 weekly
Hoskin et al 201519 (RCT,
470 patients)
Single 8 Gy fraction of
radiotherapy v ibandronate
infusion in metastatic prostate
cancer
Locally advanced lung cancer
Pooled symptom response rates not reported due to study
heterogeneity.
Possibly better 1 year overall survival with higher dose regimens
for patients with good performance status (33.3% (11.4% to 46.2%)
v 25.6% (9.4% to 45.7%)), but unclear due to high study
heterogeneity (n=1081, 8 trials).
No survival improvement seen in poor performance status patients
(risk ratio 0.96 (0.91 to 1.02) (n=911, 7 trials)
Control of thoracic symptoms,
overall survival
Time point varied between trials
Stevens et al 201520 (SR,
3576 patients, 14 RCTs)
Various palliative radiotherapy
regimens
After high and low dose regimens, complete resolution of
haemoptysis reported by 73.7% v 68.9% (P=0.19), improvement
reported by 80.2% v 81.2%; 48.2% v 53.5% reported improved
cough (P=0.04); 57.5% v 51.9% improved chest pain (P=0.43 with
significant heterogeneity between studies).
Individual RCTs reported improvement in shortness of breath in
35-40%22-24
One trial reported median time to response 5-7 weeks.24
1 year overall survival higher with high dose regimens (26.5% v
21.7%, P=0.002), at the expense of significantly increased
oesophagitis
Control of thoracic symptoms,
overall survival
Time point varied between trials
Fairchild et al 200821 (SR,
3473 patients, 13 RCTs)
Various palliative radiotherapy
regimens
Locally advanced oesophageal and gastric cancer
Improved swallowing function reported by 69%, median time to
benefit 4 weeks, duration of response 5.5 months
Dysphagia response at 56 days,
survival, toxicity
Kassam et al 200825 (phase
I/II, 39 patients)
External radiotherapy (40 Gy
in 20 fractions, twice daily)
Duration of dysphagia relief increased with radiotherapy (7 v 3
months, P=0.002).
Median overall survival increased with radiotherapy (180 v 120 days,
P=0.009)
Duration of dysphagia relief after
stenting, overall survival
Javed et al 201026 (RCT, 84
patients)
Oesophageal stenting with or
without external radiotherapy
Improved duration of dysphagia relief with radiotherapy: at 200 days,
69.6% had not experienced a dysphagia event v 51.8% without
radiotherapy (P=0.014 in multivariable modelling).
No significant improvement in overall survival
Dysphagia relief, overall survivalRosenblatt et al 201027 (RCT,
219 patients)
Oesophageal brachytherapy
with or without external
radiotherapy
Gastric bleeding reduced in 74% of patients (pooled analysis). Small
numbers reported for pain and obstruction responses (n=18 and
33)
Reduction in gastric bleeding
(response definitions varied)
Tey et al 201728 (SR, 122
patients, 7 retrospective
studies)
Palliative radiotherapy for
advanced gastric cancer
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Table 1 (continued)
ResultsEndpointsStudy and sample sizeTreatments assessed
Malignant spinal cord compression
No significant differences in mobility (P=0.86), local control (P=0.51),
or survival (P=0.68).
41.3% reported improved motor function after treatment, and 47.1%
remained stable. Improvement in ambulation not reported. Median
overall survival 3.2 months
Motor function at 1 month, local
control, overall survival
Rades et al 201629 (RCT, 203
patients (155 assessable))
20 Gy in 5 fractions v 30 Gy
in 10 fractions radiotherapy
No significant difference in response rates or duration (P=0.40):
median duration of response 5 months; median overall survival 4
months.
53% (95% CI 47% to 58%) achieved a pain response (25% (21%
to 31%) complete resolution). 27% of non-ambulatory patients
regained mobility after treatment (only 4% for those with paraplegia
before treatment). 27% with sphincter disturbance regained control.
Acute side effects were equivalent
Symptom control (pain, motor,
and sphincter function) at 1
month, toxicity, duration of
response, overall survival
Maranzano et al 200930
(RCT, 327 patients (303
assessable))
8 Gy single fraction v 16 Gy
in 2 fractions radiotherapy
No significant difference in response rates or duration: median
duration of response 3.5 months; median overall survival 4 months.
56.9% (51.1% to 62.7%) achieved a pain response (33.3% (27.7%
to 38.9%) complete resolution). 35% of non-ambulatory patients
regained mobility (not anyone with paraplegia). 14% with sphincter
disturbance regained control.
Acute side effects were equivalent
Symptom control (pain, motor,
and sphincter function) at 1
month, toxicity, duration of
response, overall survival
Maranzano et al 200531
(RCT, 300 patients (276
assessable))
16 Gy in 2 fractions v split
course (total dose 30 Gy in 8
fractions)
Post-treatment ambulation rates 84% with surgery v 57% with
radiotherapy alone (odds ratio 6.2 (2.0 to 19.8), P=0.001).
Continence was more likely after surgery, and doses of
corticosteroids (P=0.009) and opiates (P=0.002) were lower.
Median survival 126 days after surgery v 100 days after radiotherapy
alone (multivariable analysis HR 0.60 (0.38 to 0.96), P=0.033)
Mobility (time point unclear),
continence, corticosteroid use,
pain control, overall survival
Patchell et al 200532 (RCT,
101 patients (study stopped
at interim analysis))
Radiotherapy (30 Gy in 10
fractions) with or without
surgical decompression
Brain metastases
All patients received dexamethasone. No difference in overall
survival with or without WBRT (median survival 9.2 weeks v 8.5
weeks, HR 1.06 (0.90 to 1.26)), or quality of life (mean QALY 46.4
v 41.7 days).
Overall survival, quality of life
(measured in QALYs), use of
corticosteroids
Mulvenna et al 201633 (RCT,
538 patients)
Whole brain radiotherapy
(WBRT) (20 Gy in 5 fractions)
v dexamethasone alone in
non-small cell lung cancer
Unable to recommend one WBRT regimen over others due to lack
of quality of life outcomes and no overall improvement in overall
survival (n=3645, 8 trials).
No improvement in survival (HR 1.08 (0.98 to 1.18)) or symptom
control with addition of radio-sensitising drugs to WBRT. Toxicity
increased. (n=2016, 6 trials).
Addition of stereotactic radiotherapy to WBRT improved cerebral
control (n=464, 3 trials). Improvement in overall survival only in
Overall survival, cerebral disease
control, quality of life and
symptom control
Tsao et al 201234 (SR, 10 835
patients, 39 trials)
Effectiveness and adverse
events after WBRT for adults
with multiple brain metastases
individuals with a single metastasis and good performance status
in one trial (n=333) (6.5 months v 4.9 months, P=0.03). Significantly
reduced steroid doses after stereotactic radiotherapy shown in one
trial (n=333) (52% v 33%, P=0.016).
Addition of WBRT to stereotactic radiotherapy improved cerebral
control (HR 2.61 (1.68 to 4.06), P<0.001) in pooled analysis (n=577,
3 trials) but not overall survival (HR 0.98 (0.71 to 1.35), P=0.88)
(n=218, 2 trials)
Addition of WBRT resulted in lower CNS recurrence at 1 year (73%
recurrence-free v 27%, P<0.001). This was at the cost of a higher
probability of significantly reduced total recall at 4 months (mean
posterior probability 52% v 24%). This difference persisted at 6
months. In practise, to avoid cognitive decline, regular MRI
surveillance is often preferred over WBRT36
Neurocognitive outcomes at 4
months, cerebral disease control
Chang et al 200935 (RCT, 58
patients (trial stopped early
after interim analysis))
Neurocognitive outcomes
after stereotactic radiotherapy
with or without WBRT.
Head and neck cancer
80% had an objective response at 2 weeks after treatment, 67%
reported improved pain control, 33% felt their ability to eat solids
was improved, 62% reported improved overall quality of life.
74% of patients experienced significant dysphagia during treatment,
resolving by 4 weeks later.
Median overall survival was 6.1 months (range 0.5–21) and
progression-free survival 3.9 months (0.5–21).
Response rate, symptom control,
quality of life, and toxicity.
Overall and progression-free
survival
Porceddu et al 200737 (phase
II, 37 patients)
30 Gy in 5 fractions
radiotherapy delivered every
3 days
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Table 1 (continued)
ResultsEndpointsStudy and sample sizeTreatments assessed
53% objective response rate. Median overall survival 5.7 months
(95% CI 3.4 to 9.3) and progression-free survival 3.1 months (2.2
to 6.1).
85% of patients experienced improved or stable dysphagia after
treatment, 56% experienced improved pain control, 44% reported
improved overall quality of life
Response rate, symptom control,
quality of life, and toxicity.
Overall and progression-free
survival
Corry et al 200538 (phase II,
35 patients)
42 Gy in 12 fractions
radiotherapy delivered twice
daily in 4 fraction blocks
repeated 4 weekly
Bladder cancer
No significant difference for any endpoint (overall survival HR 0.99
(0.82 to 1.21), P=0.933).
51.4% reported symptom improvement (P=0.421 for comparison
between arms).
In patients experiencing these symptoms initially; haematuria
improved in 88%; urinary frequency in 82%; nocturia in 64%, and
dysuria in 72% of assessable patients at 3 months after treatment.
Median overall survival 7.5 months
Symptomatic improvement at 3
months.
Overall survival
Duchesne et al 200039 (RCT,
500 patients (272 assessable
at 3 months))
35 Gy in 10 fractions v 21 Gy
in 3 fractions radiotherapy
Rectal cancer
Improvements in pain (77% (54% to 100%)), rectal dysfunction (90%
(71% to 100%)), and bleeding (100%)
Symptomatic improvement at 3
months
Cameron et al 201640
(prospective multicentre, 51
patients)
30-39 Gy in 10-13 fractions
Gynaecological malignancies
Wide heterogeneity in studies with variable time points and poor
reporting limited this analysis. Bleeding improvement ranged from
45% to 100% of patients, pain reduction 31-100%, and discharge
15-100%. Toxicity not consistently reported
Symptomatic improvementvan Lonkhuijzen et al 201141
(SR, 476 patients, 7
retrospective studies, 1
prospective study)
Any external radiotherapy or
brachytherapy regimen
delivered palliatively to the
cervix
Locally advanced prostate cancer
Pooled response rates were 73% for haematuria, 80% pain, 63%
bladder outlet obstruction, and 78% rectal symptoms.
Toxicity was mild/moderate, though not systematically recorded.
No reports of quality of life or patient reported outcomes
Symptomatic improvement,
quality of life, toxicity
Cameron et al 201442 (SR,
315 patients, 9 retrospective
studies)
Any palliative radiotherapy
regimen delivered to the
prostate
RCT=Randomised controlled trial, SR=Systematic review, all phase II studies were non-randomised. OR=odds ratio. HR=hazard ratio. QALY=quality adjusted life
year. CNS=central nervous system. MRI=magnetic resonance imaging.
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Table 2| Management of the acute side effects of palliative radiotherapy by organ or tissue
Supporting evidenceManagementSide effectsAnatomical
site
Rate of flare significantly reduced with
dexamethasone (26% v 35%, P=0.05) (RCT, 298
patients)76
Oral dexamethasone 8 mg once daily before
treatment and for 4 days after, possibly with oral
proton pump inhibitor
35% of patient in the first week after
treatment to bone metastases experience a
pain flare. This resolves within a median of
3 days76 77
Bone
Limited evidence supporting any specific
intervention (SR, 326 patients, 9 studies)78
Routinely managed with medication (such as weak
opioids)
Cough after treatment is not well documented
but common in practice
Lung
Recommendation based on a recent literature
review as no randomised evidence was identified
to inform acute supportive management79
Antacid mixed with local anaesthetic, simple
analgesia, proton pump inhibitors, and soft bland
diet. Dietetic referral and enteral feeding maybe
required, particularly in patients with compromised
swallow before treatment
Oesophagitis results in odynophagia or
dysphagia in 14-22% of treated lung cancer
patients (SR)20 21 79 and 28% of oesophageal
cancer patients.25
Chest discomfort within the first few weeks
after treatment
Mediastinum
5-HT
3
 antagonists reduced emesis compared with
conventional antiemetics or placebo (SR of RCTs)
and are recommended in international
guidelines81 82
Antiemetics 30-60 minutes before, during, and after
treatment (such as 5-HT
3
 receptor antagonists)
Nausea (such as seen during treatment to
bone metastases in 61% or treatment for
rectal cancer in 36%)40 80
Bowel or
stomach
Recommendation based on regional guidelines
and palliative prescribing as no randomised
evidence identified83 84
Loperamide 2-4 mg and hyoscine butylbromide 20
mg as required. If diarrhoea severe (>6 bowel
movements daily) or fails to improve within 12
hours, discuss with the treating oncology team
Diarrhoea and abdominal discomfort during
treatment for pelvic tumours in 20-40%,39 40 42
resolves within 6 weeks
Recommendation based on regional practise as
no randomised evidence identified.85
Four small RCTs investigated role of cranberry
supplements; two found reduced cystitis86
Simple analgesia, good fluid intake, and
anticholinergic agents are used in routine care.
Cranberry capsules can be considered
Dysuria, frequency, and nocturia. During the
first few weeks after treatment in 33% and
20% of bladder and prostate cancer patients
treated to the primary tumour39 42
Bladder
Standardised mean difference in fatigue −0.27
(95% CI −0.37 to −0.17) with exercise (MA, 2648
patients, 38 trials).87
Small RCTs of psycho-stimulants show mixed
results in cancer related fatigue (SR).88-90 No
evidence in whole brain radiotherapy specifically
Exercise, as possible, has been shown to reduce
fatigue in cancer patients generally
FatigueBrain
Recommendation based on routine palliative care
prescribing84
Simple analgesia with dexamethasone 4 mg once
daily if persistent
Headache (32%)33
Recommendation based on routine palliative care
prescribing84
Antiemetics (such as cyclizine) and dexamethasone
if persistent
Nausea and vomiting (10-16%)
No randomised evidence identified91Otitis externa is often asymptomatic, steroid drops
can be used if troublesome
Otitis externa (5%)
Recommendation based on regional guidelines92 93
as no strong conclusions reached in two literature
reviews94-96
Daily washing, unperfumed emollient creams or
soaps, and non-adhesive dressings. For more
severe reactions (with skin breakdown) the treating
department should be contacted for advice
Sunburn-like erythema over treated area,
peaks late in treatment and for about 10 days
afterwards. Severity is dictated by dose
Skin
Information and alternative approaches to hair loss
are available through a variety of websites99 100
Wig referral before treatment can be arranged,
although timing this can be difficult in the palliative
setting
Hair loss (most patients undergoing palliative
radiotherapy to brain)33 97 98
No strong conclusions were reached for the
management of existing mucositis in multiple
SRs.101-103 Recommendations reflect national and
international guidelines.101 104 105
Enteral feeding was required in 12% of patients in
one observational UK series68
Oral hygiene, regular mouth washes (such as
saline, sodium bicarbonate), topical analgesia or
gels, nebulised saline and analgesia (including
NSAIDs and opiates in appropriate formulations).
Concerns for swallowing safety and nutritional
status should be discussed with the treating team
Oral or pharyngeal mucositis (63%) with pain
and thickened secretions.37 Dysphagia
(85%)37 and risk of aspiration pneumonia.
Side effects peak at the end of treatment to
two weeks beyond, then resolve over a
month
Oral cavity
and
oropharynx
RCT=randomised controlled trial, SR=systematic review, MA=meta-analysis, NSAID=non-steroidal anti-inflammatory drug.
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Figures
Fig 1 Linear accelerator used to deliver radiotherapy
Fig 2 For radiotherapy to the head, neck, or upper chest, a close fitting mask maybe needed to ensure a consistent treatment
position
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Fig 3 Computed tomograms showing the difference in radiotherapy dose distribution between simple, conventional palliative
radiotherapy (A), and targeted stereotactic radiotherapy (B). The latter treatment plan allows a dose of roughly three
times greater biological effectiveness to the target with significantly lower dose to surrounding tissue
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